ASK PHARM(SZ:002755)2025-01-22 09:05Financial Performance - The company expects a net profit of between 15,000 and 19,500 million yuan for the year 2024, compared to a loss of 14,852.98 million yuan in the same period last year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses is projected to be between 11,600 and 15,000 million yuan, up from a loss of 22,747.09 million yuan last year[3] - Basic earnings per share are anticipated to be between 0.17 and 0.22 yuan, recovering from a loss of 0.16 yuan per share in the previous year[3] Revenue Growth - The increase in revenue is attributed to rapid sales growth in anti-infection and chronic disease products, leading to improved profitability[5] Cost Management - The company has reduced R&D expenses by focusing on the analysis and optimization of key projects, resulting in a year-on-year decrease in R&D costs[5] - Significant cost control measures have been implemented, leading to a reduction in unit production costs and optimization of various expense categories[5] Cautionary Note - The financial data presented is preliminary and subject to final confirmation in the 2024 annual report, urging investors to exercise caution[7]